Block Listing 6-month review

Hikma Pharmaceuticals Plc
05 April 2007



Block Listing - Six Monthly Review


Name of Company:                                           Hikma Pharmaceuticals PLC

Name of scheme:                                            Hikma Pharmaceuticals PLC 2004 Stock Option Plan

Period of return:                           From:          10 October 2006        To:        5 April 2007

Balance under block scheme:                                3,193,200 ordinary shares of 10 pence each

The amount by which the block scheme has been increased,   Nil
if the scheme has been increased since the date of the
last return:

Number of securities issued/allotted under scheme during   1,473,800 ordinary shares of 10 pence each
period:

Balance under scheme not yet issued/allotted at end of     1,719,400 ordinary shares of 10 pence each
period

Number and class of securities originally listed and the   166,537,951 ordinary shares of 10 pence each originally
date of admission                                          listed on 1 November 2005

Total number of securities in issue at the end of the      169,137,407 ordinary shares of 10 pence each
period

                                    - ENDS -

Enquiries:


Hikma Pharmaceuticals PLC

Henry Knowles, Company Secretary                             [phone]

Susan Ringdal, Investor Relations Director


Notes to Editors


About Hikma

Hikma Pharmaceuticals PLC is a multinational pharmaceutical group focused on
developing, manufacturing and marketing a broad range of both branded and
non-branded generic and in-licensed pharmaceutical products. Hikma's operations
are conducted through three businesses: Generic, Branded and Injectable
Pharmaceuticals. Hikma's operations are based principally in the United States,
the Middle East and North Africa ('MENA') region and Europe. In 2006, the Group
had revenue of $317 million and profit attributable to shareholders of $54.5
million. For news and other information, please visit www.hikma.com.


                      This information is provided by RNS
            The company news service from the London Stock Exchange